Citations

Clear

409 citation(s) found for "Rivera, A".

Abstract Fri086: CD38 NADase Suppresses Sulfite Oxidase (SUOX) and Activates Reverse Complex V to Promote Metabolic Remodeling in Endothelial Cells (ECs) Under Disturbed Flow
Ko, Kyung Ae , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Rivera, Luis Antonio, KIM, JUNG HYUN, Ostos-Mendoza, Kelia, Deswal, Anita, Pathania, Rajneesh , Morrell, Craig, Chini, Eduardo N. , Martin, James, Hamilton, Dale, Seeley, Erin, Burks, Jared, Brookes, Paul, LE, NHAT TU, Abe, Junichi, Kotla, Sivareddy , Lee, Jonghae , Chen, Weiqing , Hoang, O.N. , Zhang, Aijun , Imanishi, Masaki , Mendoza, Keila Carolina Ostos , Morrell, Craig , Shen, Ying , Hamilton, Dale J. , Burks, Jared K , Wang, Guangyu

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 28, 2026 | Volume: 46 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.46.suppl_1.fri086 Get It

Introduction: Atherosclerotic lesions preferentially form in arterial regions exposed to disturbed flow (DF), where ECs exhibit mitochondrial (mt) dysfunction, metabolic reprogramming, and senescence. Hippo pathway kinases LATS1/2 maintain EC homeostasis, but how DF–mediated LATS1/2 suppression drives EC metabolic remodeling remains unclear. Hypothesis: We propose that DF activates CD38, leading to mt dysfunction and metabolic reprogramming that promotes EC senescence and aberrant proliferation by LATS1/2 inhibition. Methods: EC-specific Lats1/2 knockout mice were generated using tamoxifen-inducible Cre systems, and DF was induced by partial carotid ligation. Murine and human plaques were analyzed using COMET™ immunofluorescence, and spatial metabolomics. Bioenergetic profiling included Seahorse XF analysis, 13 C-glucose/ 13 C-glutamine tracing, and pharmacologic modulation of CD38, mtROS, and ATP synthase. Results: Complete Lats1/2 deletion caused fatal edema and vascular leakage, while partial loss produced fragile, highly neovascularized plaques. Spatial proteomics revealed a CD38-driven senescence-associated stemness (SAS) phenotype under LATS1/2 deficiency. Metabolomics showed sulfite and taurine accumulation, consistent with SUOX deficiency. Mechanistically, CD38 suppressed SUOX, induced Complex V reverse-mode , increased succinate flux, and accelerated ATP consumption. Despite ATP depletion, glutamate metabolism and TCA cycle flux were enhanced, sustaining EC proliferation under energetic stress. LATS1/2 knockdown reduced mt respiratory capacity (lower OCR peak) without significantly increasing glycolysis, and DF suppressed both OCR and ECAR, indicating impaired energy metabolism under pathological shear stress. CD38 inhibition restored mt respiration and glycolytic capacity by preserving NAD, and rescuing LATS1/2 and DF-mediated defects. Blocking reverse-mode Complex V reduced DF- and LATS1/2-dependent EC senescence and proliferation. Conclusion: Complete LATS1/2 deletion causes fatal vascular leakage, while partial loss drives plaque formation with fragile neovessels through a CD38-dependent SAS phenotype. CD38 suppresses SUOX, induces Complex V reverse-mode , increases succinate flux, and accelerates ATP consumption, enabling EC proliferation despite energy stress. DF and LATS1/2 loss impair mt and glycolytic function, whereas CD38 inhibition restores mt respiration and reduces EC senescence and proliferation to prevent atherothrombosis in DF regions.
Partitioning of parental histones between leading and lagging strands is modulated by DNA polymerase dosage
Dickinson, Quinn , Karri, Srinivasu , Kenmogne, Odile Djom, Zhu, Shuang, Ye, Zhenqing, Gan, Haiyun , Yu, Chuanhe , Gan, Haiyun , Yu, Chuanhe , Kenmogne, Odile, Rivera‐Mulia, Juan Carlos , Wang, Zhiquan

Mayo Clinic

Nucleic Acids Research | July 28, 2026 | Volume: 54 | Issue: 15 | Pages: No page available

10.1093/nar/gkag787 | PMID 42581759 Get It

Abstract Epigenetic inheritance relies on the precise recycling of parental histones during DNA replication. The N-terminal region of Pol1, the catalytic subunit of DNA polymerase α, has previously been implicated in chaperoning parental histone recycling. In this study, we identify a single amino acid mutation in the C-terminal region of Saccharomyces cerevisiae Pol1 (pol1-F1396S) that destabilizes the protein and disrupts the transfer of parental histones to the lagging strand during DNA replication. As a primary consequence, pol1-F1396S cells exhibit decreased chromatin stability. Furthermore, we demonstrate that the cellular abundance—or dosage—of all three DNA polymerases (Pol α, Pol δ, and Pol ε) influences the distribution of parental histones between the leading and lagging strands, revealing a dosage-sensitive mechanism of epigenetic regulation during DNA replication.
A Cost-Effective High Task Alignment Model for Ultrasound-Guided Central Venous Catheterization Training
Gomaa, I, Damon, Aaron, Chorro, Rosa Anna, Olson, Helga N, Johnson, Jimmy A. , Stites, A. C., Rivera, Mariela , Kelm, D, Gomaa, Ibrahim A. , Stites, Andrew J , Morrey, Mark, Kelm, Diana, Damon, Aaron , Morrey, Mark E. , Kelm, Diana J.

Mayo Clinic

ATS Scholar | July 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/atsscholar/aapag033 | PMID 42406409 Get It

Abstract Background Central venous catheterization (CVC) is a fundamental procedural competency in pulmonary and critical care medicine (PCCM). Although commercially available task trainers are effective for teaching CVC placement, their high cost and logistical requirements can limit access to repeated practice. Objective To evaluate learner and faculty perceptions and usability of a newly developed CVC simulation model compared with a standard commercial task trainer and detail the technical report of the novel model’s construction. Methods We conducted a prospective educational evaluation during the PCCM CVC workshop. Participants practiced CVC placement with both the standard commercial trainer and a locally constructed simulation model developed at our institution. Teaching faculty were asked to evaluate both models from an instructional standpoint. Results Eighteen participants (15 PCCM 1st year fellows and 3 faculty instructors) evaluated the novel CVC simulation model. All fellows (n = 15, 100%) preferred the new model over a standard commercial model, with 14 (93%) reporting improved understanding of CVC insertion steps and 11 (73%) noting ease of ultrasound landmark identification. All fellows (n = 15, 100%) endorsed inclusion of the model in future workshops. Additionally, faculty instructors preferred the novel model for teaching (n = 3, 100%). All faculty supported future use of the model. The initial model development cost was approximately $288.96 with most materials’ reusable. Conclusions The novel task-aligned CVC simulation model offers a realistic, reusable, and cost-effective alternative to commercial simulators, with high learner and faculty preference and strong educational value. Its functional alignment supports integration into fellowship training, with future studies needed to assess objective skill acquisition and retention.
Slow-wave sleep across the Alzheimer's disease continuum: cognitive trajectories and sex differences
Fernández‐Arcos, Ana, Mayà, Gerard, Hernández, Laura, Knezevic, Iva, Soldevila-Domenech, Natalia, Zetterberg, Henrik, Blennow, Kaj, Grinberg, Lea T, Muñoz-Lopetegi, Amaia, Martín‐Sobrino, Isabel, Arqueros, Aurora, GAIG, CARLES, Lladó, Albert, Val-Guardiola, Andrea, Iranzo, Álex, Study, Alfa, Tort‐Colet, Núria , Mayà, Gerard , Stankeviciute, Laura S , Minguillón, Carolina , Soldevila‐Domenech, Natalia , Sánchez‐Benavides, Gonzalo , Kassinopoulos, Michalis , Suárez‐Calvet, Marc , Holst, Sebastian C. , Zetterberg, Henrik , Blennow, Kaj , Grinberg, Lea T. , Muñoz‐Lopetegi, Amaia , Martín-Sobrino, Isabel , Montini, Angelica , Gaig, Carles , Lladó, Albert , Sánchez‐Valle, Raquel , Piñol‐Ripoll, Gerard , Val‐Guardiola, Andrea, Iranzo, Álex , Gispert, Juan Domingo , Molinuevo, José Luís , Falgàs, Neus , Grau‐Rivera, Oriol

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9844198/v1 Get It

Abstract Background Sleep disturbances are common in Alzheimer's disease and have been reported in its preclinical stage. A detailed characterization of sleep disruption across the Alzheimer’s disease continuum is required to clarify its role as a potential therapeutic target and to evaluate the utility of sleep-related biomarkers. Methods Sleep architecture was characterized through detailed spectral and temporal analysis of the slow-wave activity using polysomnography across the Alzheimer’s disease continuum . Participants included: cognitively unimpaired individuals without abnormal Alzheimer’s disease biomarkers (n = 30), cognitively unimpaired individuals with abnormal Alzheimer’s disease biomarkers (n = 45), and individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease (n = 41). Associations between slow-wave features and longitudinal cognitive performance were tested in cognitively unimpaired participants. Sex differences were also explored. Results A stepwise increased wake after sleep onset and latency to rapid eye movement sleep was observed, alongside reduced spectral power of slow-wave activity and a progressive flattening of slow-waves across the Alzheimer’s disease continuum in both sexes. In cognitively unimpaired individuals, higher slow-wave slope and greater peak-to-peak amplitude were associated with better cognitive trajectories over time. Conclusions Sleep macro- and microarchitecture are altered early and progressively deteriorate across the Alzheimer’s disease continuum . Slow-wave features relate to cognitive trajectories in preclinical Alzheimer’s disease, with exploratory analyses suggesting stronger associations in men. These findings support slow-wave morphology as a candidate non-invasive marker for future sleep-based intervention studies.
Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications
Miller, Melanie J., Kanoria, Shaveta , Aisen, Paul S., Beckett, Laurel A., Green, Robert C., Harvey, Danielle J., Jack, Clifford R., Jagust, William, Lee, E, Nho, Kwangsik, Nosheny, Rachel, Okonkwo, Ozioma C., Perrin, Richard J., Petersen, Ronald C., Saykin, Andrew J., Shaw, Leslie M., Toga, Arthur W., Tosun, Duygu, Landau, Susan M, Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Harvey, Danielle , Weiner, Michael W , Harvey, Danielle J , Veitch, Dallas P. , Miller, Melanie J. , Aisen, Paul , Beckett, Laurel , Green, Robert C. , Jack, Clifford R. , Jagust, William J. , Nho, Kwangsik T. , Nosheny, Rachel, Perrin, Richard J. , Petersen, Ronald C. , Mindt, Mónica Rivera , Saykin, Andrew J. , Shaw, Leslie M. , Toga, Arthur W. , Landau, Susan , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | June 18, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71566 | PMID 42309987 Get It

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) recently celebrated its 20th anniversary, reflecting two decades of major contributions to Alzheimer's research through open data sharing and longitudinal multimodal assessments. This review synthesizes 122 high‐impact studies using ADNI data or biospecimens from 2023 to mid‐2025 to clarify mechanisms of Alzheimer's disease (AD) progression. Studies describe impairment of glymphatic clearance and the impact of cerebral small vessel disease, trajectories of amyloid beta and tau deposition, inflammation, metabolic disturbances, synaptic dysfunction, and neurodegeneration, leading to cognitive impairment and neuropsychiatric symptoms. Multifactorial contributions from genetic and epigenetic influences, co‐pathologies and comorbidities, and mechanisms of resilience modulate disease progression. Finally, heterogeneity of clinical presentation and disease course is described in the context of multiple contributing factors, highlighting the complexity of AD. By integrating imaging, fluid biomarkers, genetics, and clinical measures, ADNI provides a comprehensive research dataset for unraveling mechanisms underlying AD progression.
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
Castaneda, Regina , Bechenati, Dima , Espinosa, Maria A., Villamarin, Jose L. , Tama, Elif , Safwan, Nancy , Fansa, Sima , Verastegui, Alfredo , McNally, Allyson W, Meek, Jesse L., Rajjo, Tamim , Shufelt, Chrisandra , Bechenati, Dima , Rivera Gutierrez, Rene de J , Espinosa, Maria A , Villamarin, Jose , Tama, Elif , Safwan, Nancy , Fansa, Sima , Verastegui, Alfredo , McNally, Allyson W , Mara, Kristin C , Winham, Stacey J , Rajjo, Tamim I , Acosta, Andres , Faubion, Stephanie S , Shufelt, Chrisandra L , Hurtado, Maria Daniela , Castaneda, Regina , Gutiérrez, René de Jesús Rivera , Mara, Kristin C. , Winham, Stacey J. , Acosta, Andrés , Faubion, Stephanie S. , Hurtado, Maria D.

Mayo Clinic

Obesity | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/oby.70231 | PMID 42290037 Get It

ABSTRACT Objective This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real‐world clinical practice. Methods We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years). Results Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, p < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, p = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain‐promoting medications, and higher tirzepatide dosage. Age was not an independent predictor. Conclusions Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex‐specific considerations into personalized obesity treatment strategies.
Top 5 Surgical Education Innovations for Low‐Resource Settings Over the Last 50 years
Choubey, Udit , Mbanje, Cassandra , Tak, Rajeeka Singh , Davies, Jessica , Rivera, Mariela , Rivera, Mariela , Mbanje, Cassandra Phillippa Tatenda

Mayo Clinic

World Journal of Surgery | June 9, 2026 | Volume: 50 | Issue: 8 | Pages: 2188-2194

10.1002/wjs.70443 | PMID 42261130 Get It

Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Uysal, Utku, Landazuri, Patrick , Patra, Sanjay, Crudele, Angela, Englot, Dario, Gavvala, Jay R., Tandon, Nitin, Pati, Sandipan , Kaye, Lesley , Ojemann, Steven, Barnett, Daniel, Neimat, Joseph, Palade, Adriana , Rahimpour, Shervin, Arain, Amir A., Cash, Sydney S., Salanova, Vicenta , Urban, Alexandra, Welch, W. Pete, Gonzalez-Martinez, Jorge A., Spencer, David, Rivera‐Cruz, Angélica , Dugan, Patricia, Fajardo, Marytery , Lallas, Matt, Odom, Nicole, Roland, Jarod L. , Willie, Jon T., Sheth, Sameer A., Skidmore, Christopher T., Drees, Cornelia , Parker, Jonathon, Szaflarski, Jerzy P. , Johnson, Lise, Norman, Jacob F. , Wingeier, Brett, Group, Nautilus Study, Group, Nautilus Study, Englot, Dario J. , Englot, Dario J , Richardson, Robert Mark , Van Gompel, Jamie J , Starnes, Keith , Ernst, Lia D , Amin, Ushtar , Roland, Jarod L , Goldman, Alica M , Wu, Chengyuan , Drees, Cornelia , Ganguly, Taneeta Mindy , Szaflarski, Jerzy , Johnson, Lise , Norman, Jacob F , Landazuri, Patrick , Burdette, David E. , Patra, Sanjay , Gavvala, Jay R. , Tandon, Nitin , Pati, Sandipan Bankim Behari , Kaye, Lesley C , Ojemann, Steven , Neimat, Joseph S. , Rahimpour, Shervin , Arain, Amir M. , Cash, Sydney S. , Urban, Alexandra , González-Martínez, Jorge , Gompel, Jamie J. Van , Ernst, Lia , Dugan, Patricia , Jobst, Barbara C. , Willie, Jon T , Sheth, Sameer A. , Goldman, Alica M. , Skidmore, Christopher , Wu, Chengyuan , Parker, Jonathon J. , Ganguly, Taneeta M. , Ghatan, Saadi , Wingeier, Brett , Seale, Cairn G. , Morrell, Martha J.

Mayo Clinic

Epilepsia | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70321 | PMID 42233958 Get It

Abstract Objective This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.
Colchicine Directly Targets Aldehyde Dehydrogenase 2 (ALDH2) to Suppress Radiation-Induced Senescence and Atherosclerosis
Abe, Jun‐ichi , Samanthapudi, Venkata Subrahman K, Chen, Weiqing , Tra, Ngoc Tuyet , Mejia, Gilbert F. , Hoang, Oanh, Rivera, Luis Antonio, Chu, Kun Yuan, Osawa, Masaki, Kim, J, Ko, Kyung Ae , Reddy, Anilkumar K. , Moreno, Silvia Fernanda López, Lenz, S., Mendoza, Keila Carolina Ostos , Sanchez, Edgardo, Herrmann, Joerg , Schadler, Keri , Manisty, Charlotte, Yusuf, Syed Wamique , Pathania, Rajneesh , Nead, Kevin T. , Hildebrandt, Michelle, Fuller, C David, Lin, Steve H., Le, Nhat‐Tu , Manisty, Charlotte , Hoang, O.N. , Kim, Jung Hyun , Hoang, Oanh , Abe, Jun-Ichi , Chen, Weiqing , Rivera, Luis Antonio , Kim, Jung Hyun , Lee, Jonghae , Li, Shengyu , Lenz, Stefania Assunto , Herrmann, Joerg , Schadler, Keri , Yvan-Charvet, Laurent , Ameri, Pietro , Yusuf, Syed Wamique , Burks, Jared K , Palaskas, Nicolas L , Fuller, Clifton D. , Koutroumpakis, Efstratios , Krishnan, Sunil , Wang, Guangyu , Kotla, Sivareddy

Mayo Clinic

No container title available | May 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.25.726409 Get It

Abstract Background Ionizing radiation (IR) accelerates atherosclerosis through induction of cellular senescence, DNA damage, defective efferocytosis, and dysregulation of clonal hematopoiesis (CH) drivers. Although low-dose colchicine reduces ischemic cardiovascular events in coronary artery disease, the precise molecular mechanisms underlying its vasculoprotective effects remain incompletely defined, and whether it mitigates radiation-associated vascular injury is unknown. Methods Bone marrow–derived macrophages (BMDMs) were pretreated with low-dose colchicine and exposed to 2 Gy IR. Molecular effects were assessed by RNA-seq, immunoblotting, and molecular docking. In vivo effects were tested in a partial carotid ligation (PLCL) model using spatial proteomics. Human monocyte-derived macrophages (HMDMs) from thoracic malignancy patients were analyzed before and after radiation therapy (RT). Results Low-dose colchicine suppressed IR-induced macrophage senescence signaling while preserving NRF2 activity. In a cell-free assay, colchicine directly activated aldehyde dehydrogenase 2 (ALDH2) in a dose-dependent manner (EC 50 1–5 nM), identifying ALDH2 as a direct molecular target of colchicine. Following irradiation, colchicine restored ALDH2, reduced mitochondrial (mt)ROS - dependent p90 ribosomal S6 kinase ( p90RSK ) activation and lipid peroxidation, preserved TET2 and DNMT3A expression, and rescued impaired efferocytosis while preventing nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP) depletion. These protective effects were ALDH2-dependent, as they were lost with ALDH2 inhibition or depletion and were mimicked by pharmacologic ALDH2 activation. In vivo, colchicine attenuated radiation-induced atherosclerosis and macrophage senescence-associated stemness (SAS). Consistently, macrophages from patients after RT showed reduced ALDH2 with increased mtROS, lipid peroxidation, and senescence. Conclusion These findings identify ALDH2 as a previously unrecognized molecular target of colchicine that links mitochondrial redox control to suppression of radiation-induced macrophage senescence and atherosclerosis and may contribute to the efficacy of low-dose colchicine in cardiovascular disease.
Predictors of fibrotic progression in myeloproliferative neoplasms: A real-world retrospective cohort study.
Khan, Muhammad Ali, Ayub, Umair , Chandani, Kanishka Uttam, Foran, James M., Begna, Kebede, Al-Kali, Aref, Rivera, Candido, Pardanani, Animesh , Gangat, Naseema, Tefferi, Ayalew, Palmer, Jeanne , Foran, James M. , Al‐Kali, Aref , Gangat, Naseema , Tefferi, Ayalew , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18607 Get It

e18607 Background: Progression to myelofibrosis (MF) is associated with worse survival and influences treatment decisions, yet predictors of fibrotic progression in polycythemia vera (PV) and essential thrombocythemia (ET) remain poorly characterized. Methods: Patients with pathologically confirmed PV or ET were identified from a retrospective chart review. Demographics (age, sex, race, ethnicity), clinical features (thrombosis and bleeding history, performance status, symptom burden, organomegaly), bone marrow pathology (cellularity, trilineage hematopoiesis, megakaryocyte proliferation and atypia, fibrosis grade), molecular markers ( JAK2 , CALR , MPL , ASXL1 , EZH2 , TET2 , SRSF2 , IDH1/2 , SF3B1 , TP53 ), cytogenetics, laboratory values, and treatment history (phlebotomy, hydroxyurea, interferon, ruxolitinib) at first bone marrow biopsy were recorded. MF progression was defined as hematologist-confirmed transformation to MF. Kaplan-Meier analyses estimated median MF-free survival (MFS), defined as time to MF progression or death. Univariable followed by multivariable Cox proportional regression were performed to identify candidate MFS predictors. The proportional hazards assumption was assessed using Schoenfeld residuals. Hazard ratios (HR) with 95% confidence intervals (CI) were computed, with p<0.05 indicating statistical significance. Results: A total of 505 PV and 198 ET patients were identified. The majority were White (PV: 92%; ET: 86%). PV patients were predominantly male (54%) whereas ET patients were predominantly female (66%). MF progression occurred in 160 (32%) PV and 32 (16%) ET patients. Death was observed in 139 (28%) PV and 10 (5%) ET patients. Median MFS was 158.5 months (95% CI: 143.0-183.0) for PV and 308.0 months (95% CI: 175.0-NR) for ET. In PV, older age at diagnosis (HR 1.04; 95% CI: 1.02-1.07; p<0.001) and shorter time since PV or ET diagnosis to biopsy (HR 0.995; 95% CI: 0.990-0.999; p=0.048) independently predicted worse MFS. In ET, bone marrow hypercellularity (HR 5.67, 95% CI: 1.40-23.0, p=0.015) independently predicted worse MFS. Conclusions: PV patients demonstrated shorter MFS compared to ET. Older age at diagnosis in PV, whereas bone marrow hypercellularity in ET was significantly associated with fibrotic progression or death. Active surveillance of at-risk patients may facilitate early detection and timely treatment initiation. Disease Variable HR (95%CI) P-value PV Age at diagnosis 1.04 (1.02-1.07) <0.001 Time since PV or ET diagnosis to biopsy 0.995 (0.990-0.999) 0.048 ET Bone marrow hypercellularity 5.67 (1.40-23.0) 0.015